Heart Failure Follow-Up in Primary Care: GDMT, Weights, Labs and When to Refer

Primary-care heart failure follow-up has one job beyond keeping the patient out of the hospital: getting every eligible patient onto full guideline-directed medical therapy. For HFrEF, that means four drug classes from the 2022 AHA/ACC/HFSA guideline, each with a class 1 recommendation: an ARNI (or an ACE inhibitor or ARB when an ARNI is not feasible), one of three proven beta blockers, an MRA, and an SGLT2 inhibitor. Each visit checks volume, blood pressure, heart rate, potassium and kidney function, makes the next titration step, and reinforces daily weights and self-care. Referral comes when the patient shows signs of advanced disease or needs a device.

Classify before you treat

Two classifications drive decisions: ejection fraction picks the drugs, and stage frames prevention and prognosis.

For HFpEF, a 2026 ACC expert consensus decision pathway adds a nonsteroidal MRA and incretin-based therapy for patients with obesity; confirm the specific recommendations in the current document.

The ACC/AHA stages describe the trajectory: stage A, at risk (hypertension, diabetes, obesity, cardiotoxic exposure); stage B, pre-heart failure (structural disease, abnormal filling or elevated natriuretic peptides without symptoms); stage C, current or previous symptoms; stage D, advanced heart failure despite GDMT. Stages do not move backward; NYHA class (I to IV) does, and it describes current symptoms.

The follow-up visit

Each visit covers the same ground:

• Symptoms and function: dyspnea, orthopnea, paroxysmal nocturnal dyspnea, exercise tolerance, and NYHA class.
• Volume: the home weight log against the dry weight, jugular venous pressure, crackles, edema, hepatomegaly.
• Vital signs: seated and standing blood pressure, heart rate and rhythm. Symptomatic hypotension or a heart rate under about 50 limits titration; an asymptomatic systolic pressure in the 90s usually does not.
• Labs: basic metabolic panel (potassium, sodium, creatinine), with magnesium when on loop diuretics.
• Medications: adherence, cost, and anything that worsens heart failure, especially NSAIDs.
• Hospital and emergency visits since the last appointment.

BNP or NT-proBNP is recommended in chronic heart failure for risk stratification (class 1); it supports, but does not replace, the bedside volume assessment.

GDMT for HFrEF: drugs, doses and limits

Doses below are from the 2022 guideline's table of drugs commonly used for HFrEF.

Two further options apply to selected patients. Hydralazine with isosorbide dinitrate is recommended for patients who self-identify as African American with NYHA class III to IV symptoms on optimal therapy, and is an option for others who cannot take an ARNI, ACE inhibitor or ARB. Ivabradine is reasonable in sinus rhythm with a resting heart rate of 70 or more on a maximally tolerated beta blocker, LVEF of 35 percent or less and NYHA class II to III symptoms.

Sequencing and titration

The guideline recommends titrating to the doses proven in trials (class 1) and says titration as often as every 1 to 2 weeks, guided by symptoms, vital signs and labs, can be useful (2a). A practical pattern in a stable outpatient:

1. Start or switch to an ARNI and start an SGLT2 inhibitor; neither has a large potassium or heart rate effect that blocks the other.
2. Add a beta blocker once the patient is euvolemic.
3. Add an MRA if eGFR is above 30 and potassium is below 5.0.
4. Increase one drug at each visit every 1 to 2 weeks, checking a basic metabolic panel within 1 to 2 weeks of each RAS inhibitor or MRA change.

Low doses of all four classes are generally better than a target dose of one class and nothing else. A creatinine rise of modest size after starting an ARNI, ACE inhibitor or SGLT2 inhibitor is expected; it does not by itself justify stopping (confirm the tolerated rise in the current guideline). For potassium of 5.5 mEq/L or higher, reduce or stop the MRA, review potassium supplements and salt substitutes, and recheck.

Diuretics

Loop diuretics (furosemide, torsemide, bumetanide) relieve congestion but do not change mortality. Use the lowest dose that keeps the patient at dry weight. Adding a thiazide such as metolazone is reserved for patients who do not respond to moderate or high loop doses, because electrolyte losses rise sharply. As GDMT is titrated, diuretic needs often fall; watch for dizziness and rising creatinine from overdiuresis.

Drugs that worsen heart failure

Daily weights and self-care

Every patient should leave with a written action plan. The 2022 guideline gives a class 1 recommendation to multidisciplinary self-care support and education and does not set a single weight number; many heart failure programs use a gain of 2 to 3 lb overnight or 5 lb in a week as the trigger to call. Teach the patient and caregiver:

• Weigh every morning after voiding, before eating, in the same clothing, on the same scale, and write it down.
• Call for the weight trigger, worsening breathlessness, needing more pillows, new edema, dizziness or fainting.
• Avoid excessive sodium (2a); a specific milligram limit is individualized.
• Take every GDMT drug daily, even when feeling well, and do not stop a beta blocker abruptly.
• SGLT2 inhibitors: genital hygiene, and hold during acute illness with poor intake or before surgery as instructed.
• Avoid over-the-counter NSAIDs and decongestants.
• Stay active: exercise training is recommended (class 1) and cardiac rehabilitation can be useful (2a).
• Keep respiratory vaccinations current; vaccination is reasonable to reduce mortality (2a).

Screen for depression, cognitive impairment, low health literacy and social barriers, which predict poor self-care.

Follow-up intervals

• After hospital discharge: a structured contact within 7 days (in person, telehealth or a nurse or pharmacist call).
• During titration: every 1 to 2 weeks, with a metabolic panel after RAS inhibitor and MRA changes.
• After a significant clinical change, or after GDMT when a device is being considered: repeat echocardiography to reassess ejection fraction.
• Stable on target doses: every 3 to 6 months, sooner for any weight trigger or symptom change.

When to refer

The guideline lists clinical markers of advanced heart failure that should prompt referral to a heart failure specialist, summarized by the mnemonic I-NEED-HELP:

• Intravenous inotropes needed.
• NYHA class IIIB to IV symptoms or persistently elevated natriuretic peptides.
• End-organ dysfunction (worsening kidney or liver function).
• Ejection fraction of 35 percent or less despite GDMT.
• Defibrillator shocks.
• Hospitalizations: more than one in 12 months.
• Edema despite escalating diuretics.
• Low systolic pressure (90 or less) or high resting heart rate.
• Prognostic medication: progressive intolerance or down-titration of GDMT.

Cardiology or electrophysiology referral is also due for device evaluation. A primary prevention ICD is recommended for LVEF of 35 percent or less with NYHA class II to III symptoms on chronic GDMT, at least 40 days after myocardial infarction, with expected survival beyond 1 year. Cardiac resynchronization therapy is considered for LVEF of 35 percent or less with a wide QRS, particularly left bundle branch block. Send to the emergency department for hypoxia, chest pain, syncope, symptomatic hypotension, or potassium of 6.0 mEq/L or more with ECG changes.

How the exam tests this

• The washout trap. Starting sacubitril-valsartan the same day lisinopril is stopped ignores the 36-hour rule.
• The wrong beta blocker trap. Metoprolol tartrate or atenolol is not GDMT; carvedilol, metoprolol succinate or bisoprolol is.
• The MRA trap. Spironolactone with eGFR of 25 or potassium of 5.3 is contraindicated.
• The calcium channel blocker trap. Diltiazem for rate control in HFrEF is harmful.
• The diabetes-only trap. An SGLT2 inhibitor in HFrEF is indicated without diabetes.
• The recovered EF trap. Stopping GDMT when the ejection fraction returns to 50 percent invites relapse.
• The NSAID trap. A new decompensation after starting naproxen for knee pain is drug-induced.

Practice question

A 68-year-old man with ischemic cardiomyopathy and LVEF of 30 percent is seen for routine follow-up. He has NYHA class II symptoms and no diabetes. Medications are lisinopril 20 mg daily, carvedilol 25 mg twice daily, spironolactone 25 mg daily and furosemide 20 mg daily. Weight is stable at his dry weight and there is no edema. Blood pressure is 118/70 mm Hg, heart rate 62 and regular. Potassium is 4.4 mEq/L and eGFR is 58 mL/min/1.73 m2. Which of the following is the most appropriate next step?

• A. Add dapagliflozin 10 mg daily
• B. Stop lisinopril and start sacubitril-valsartan with the first dose this evening
• C. Increase furosemide to 40 mg daily
• D. Add hydralazine and isosorbide dinitrate

Answer: A. He is on three of the four GDMT classes and is missing an SGLT2 inhibitor, which is a class 1 recommendation in symptomatic HFrEF regardless of diabetes and is safe with his pressure, potassium and kidney function. Option B moves toward an ARNI, a reasonable later step, but starting it the same evening violates the 36-hour ACE inhibitor washout and risks angioedema. Option C intensifies diuresis in a patient who is at dry weight, risking hypotension and kidney injury. Option D is reserved for self-identified African American patients with NYHA class III to IV symptoms on optimal therapy, or for those who cannot take a RAS inhibitor.

Key points

Related NPPace guides

• Hypertension on the NP Exam: Staging, When to Start Medication and the First Drug
• Statin Decisions by ASCVD Risk: Who Gets a Statin, Which Intensity and How to Monitor
• Atrial Fibrillation in the Clinic: CHA2DS2-VASc, Anticoagulant Choice and Rate Control
• How to Read a Primary-Care Vignette Like a Provider: The 5-Step Method
• AANP vs ANCC: Which NP Certification Exam Should You Take?